Assessment of Ovarian Reserve in Patients with Migraine

Authors

  • Güzin Aykal Antalya Education and Research Hospital, Department of Clinical Biochemistry, Soguksu 07100 Antalya, Turkey https://orcid.org/0000-0002-2413-2695
  • Nurgül Uzun Antalya Education and Research Hospital, Department of Clinical Biochemistry, Soguksu 07100 Antalya, Turkey
  • Aysel Uysal Derbent Antalya Education and Research Hospital, Department of Clinical Biochemistry, Soguksu 07100 Antalya, Turkey https://orcid.org/0000-0001-6488-8385
  • Ayşenur Yeğin Antalya Education and Research Hospital, Department of Clinical Biochemistry, Soguksu 07100 Antalya, Turkey https://orcid.org/0000-0002-7856-3191

DOI:

https://doi.org/10.48208/HeadacheMed.2022.7

Keywords:

Ovarian Reserve, Migraine Disorders, anti-Müllerian hormone, Family Planning Services, Humans

Abstract

Objective

The aim of our study is to investigate the relationship between migraine and ovarian reserve. Methods

The study group consists of women between the ages of 25-51, including 44 patients diagnosed with migraine and 43 controls. Ovarian reserves were performed by antral follicle count and measured anti-Müllerian hormone level.

The cohort was divided into four subgroups according to age as follows: 30 years and below, 31-35 years, 36-40 years, and 41 years of age and above.

Results

Of the 87 individuals included in this study, 44 were migraine patients, and 43 were healthy controls. The mean ages of the study and control groups were 34.3 (minimum: 25, maximum: 51) and 36.5 (minimum: 27, maximum: 51) years, respectively. There was no statistically significant difference between the two groups regarding age (p=0.48). In the study and control groups, respectively; mean AMH levels were 2.67 ± 2.46 ng/mL and 2.55 ± 2.38 ng/mL (p=0.819), mean basal FSH levels were 7.92 ± 2.52 U/L and 9.11 ± 3.19 U/L (p=0.066), mean basal LH levels were 6.35 ± 3.59 U/L and 6.06 ± 2.86U/L (p=0.681), mean basal estradiol levels were 65.02 ± 69.54 ng/L and 49.47 ± 27.08 ng/L (p=0.244), and mean AFC were 10.9 ± 3.9 and 10.2 ± 3.7 (p=0.435). Between subgroups aged ≤30 years, serum anti-Müllerian hormone levels were found to be significantly different (p=0.036). There was no statistically significant difference between any age subgroups in terms of antral follicle count.

Conclusion

In conclusion, detecting possible reduction of ovarian reserves in reproductive-age (especially younger than 30 years) migraine patients by utilizing anti-Müllerian hormone and ultrasonographic markers would allow these women to make cognizant decisions regarding marriage and family planning, as well as inform them whether they are in early menopause risk

Downloads

Download data is not yet available.

References

Todd C, Lagman-Bartolome AM and Lay C. Women and Migraine: the Role of Hormones. Curr Neurol Neurosci Rep 2018;18(7):42 Doi:10.1007/s11910-018-0845-3 DOI: https://doi.org/10.1007/s11910-018-0845-3

Silberstein SD. Migraine. Lancet 2004;363(9406):381-391 Doi:10.1016/s0140-6736(04)15440-8 DOI: https://doi.org/10.1016/S0140-6736(04)15440-8

Yücel YJ. Migren baş ağrısında tanı ve tedavi yaklaşımları. 2008;35(4):281-286

Martin VT. Migraine and the menopausal transition. Neurol Sci 2014;35 Suppl 1:65-69 Doi:10.1007/s10072-014-1745-1 DOI: https://doi.org/10.1007/s10072-014-1745-1

Bedenk J, Vrtačnik-Bokal E and Virant-Klun I. The role of anti-Müllerian hormone (AMH) in ovarian disease and infertility. J Assist Reprod Genet 2020;37(1):89-100 Doi:10.1007/s10815-019-01622-7 DOI: https://doi.org/10.1007/s10815-019-01622-7

Tal R and Seifer DB. Ovarian reserve testing: a user's guide. Am J Obstet Gynecol 2017;217(2):129-140 Doi:10.1016/j.ajog.2017.02.027 DOI: https://doi.org/10.1016/j.ajog.2017.02.027

Iwase A, Osuka S, Goto M, Murase T, Nakamura T, Takikawa S and Kikkawa F. Clinical application of serum anti-Müllerian hormone as an ovarian reserve marker: A review of recent studies. J Obstet Gynaecol Res 2018;44(6):998-1006 Doi:10.1111/jog.13633 DOI: https://doi.org/10.1111/jog.13633

Li L and Wang Z. Ovarian Aging and Osteoporosis. Adv Exp Med Biol 2018;1086:199-215 Doi:10.1007/978-981-13-1117-8_13 DOI: https://doi.org/10.1007/978-981-13-1117-8_13

Vollenhoven B and Hunt S. Ovarian ageing and the impact on female fertility. F1000Research 2018;7:F1000 Faculty Rev-1835 Doi:10.12688/f1000research.16509.1 DOI: https://doi.org/10.12688/f1000research.16509.1

Victoria M, Labrosse J, Krief F, Cédrin-Durnerin I, Comtet M and Grynberg M. Anti Müllerian Hormone: More than a biomarker of female reproductive function. J Gynecol Obstet Human Reprod 2019;48(1):19-24 Doi:10.1016/j.jogoh.2018.10.015 DOI: https://doi.org/10.1016/j.jogoh.2018.10.015

Maciel GAR, Baracat EC and Sá MFS. About the Anti-Müllerian Hormone (AMH) Uses in the Clinical Practice. Rev Bras Ginecol Obstet 2018;40(11):661-663 Doi:10.1055/s-0038-1676059 DOI: https://doi.org/10.1055/s-0038-1676059

Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, . . . Anderson RA. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update 2014;20(3):370-385 Doi:10.1093/humupd/dmt062 DOI: https://doi.org/10.1093/humupd/dmt062

Waziri-erameh JM and Omoti AE. Infertility and migraine in midwest Niger-Delta region. Afr J Reprod Health 2006;10(3):120-121 DOI: https://doi.org/10.2307/30032479

Martin VT, Pavlovic J, Fanning KM, Buse DC, Reed ML and Lipton RB. Perimenopause and Menopause Are Associated With High Frequency Headache in Women With Migraine: Results of the American Migraine Prevalence and Prevention Study. Headache 2016;56(2):292-305 Doi:10.1111/head.12763 DOI: https://doi.org/10.1111/head.12763

Broner SW, Bobker S and Klebanoff L. Migraine in Women. Semin Neurol 2017;37(6):601-610 Doi:10.1055/s-0037-1607393 DOI: https://doi.org/10.1055/s-0037-1607393

Kim C, Slaughter JC, Wang ET, Appiah D, Schreiner P, Leader B, . . . Wellons M. Anti-Müllerian hormone, follicle stimulating hormone, antral follicle count, and risk of menopause within 5 years. Maturitas 2017;102:18-25 Doi:10.1016/j.maturitas.2017.04.018 DOI: https://doi.org/10.1016/j.maturitas.2017.04.018

Ripa P, Ornello R, Degan D, Tiseo C, Stewart J, Pistoia F, . . . Sacco S. Migraine in menopausal women: a systematic review. Int J Womens Health 2015;7:773-782 Doi:10.2147/ijwh.S70073 DOI: https://doi.org/10.2147/IJWH.S70073

Pakalnis A. Migraine and Hormones. Semin Pediatr Neurol 2016;23(1):92-94 Doi:10.1016/j.spen.2016.01.005 DOI: https://doi.org/10.1016/j.spen.2016.01.005

Cameron KE, Kole MB, Sammel MD, Ginsberg JP, Gosiengfiao Y, Mersereau JE, . . . Gracia CR. Acute Menopausal Symptoms in Young Cancer Survivors Immediately following Chemotherapy. Oncology 2018;94(4):200-206 Doi:10.1159/000485917 DOI: https://doi.org/10.1159/000485917

Nair S, Slaughter JC, Terry JG, Appiah D, Ebong I, Wang E, . . . Wellons MF. Anti-mullerian hormone (AMH) is associated with natural menopause in a population-based sample: The CARDIA Women's Study. Maturitas 2015;81(4):493-498 Doi:10.1016/j.maturitas.2015.06.026 DOI: https://doi.org/10.1016/j.maturitas.2015.06.026

Tehrani FR, Solaymani-Dodaran M, Tohidi M, Gohari MR and Azizi F. Modeling age at menopause using serum concentration of anti-mullerian hormone. J Clin Endocrinol Metab 2013;98(2):729-735 Doi:10.1210/jc.2012-3176 DOI: https://doi.org/10.1210/jc.2012-3176

Lie Fong S, Schipper I, Valkenburg O, de Jong FH, Visser JA and Laven JS. The role of anti-Müllerian hormone in the classification of anovulatory infertility. Eur J Obstet Gynecol Reprod Biol 2015;186:75-79 Doi:10.1016/j.ejogrb.2015.01.007 DOI: https://doi.org/10.1016/j.ejogrb.2015.01.007

Steiner AZ, Herring AH, Kesner JS, Meadows JW, Stanczyk FZ, Hoberman S and Baird DD. Antimüllerian hormone as a predictor of natural fecundability in women aged 30-42 years. Obstet Gynecol 2011;117(4):798-804 Doi:10.1097/AOG.0b013e3182116bc8 DOI: https://doi.org/10.1097/AOG.0b013e3182116bc8

Davies MC and Cartwright B. What is the best management strategy for a 20-year-old woman with premature ovarian failure? Clin Endocrinol (Oxf) 2012;77(2):182-186 Doi:10.1111/j.1365-2265.2012.04408.x DOI: https://doi.org/10.1111/j.1365-2265.2012.04408.x

Podfigurna A, Lukaszuk K, Czyzyk A, Kunicki M, Maciejewska-Jeske M, Jakiel G and Meczekalski B. Testing ovarian reserve in pre-menopausal women: why, whom and how? Maturitas 2018;109:112-117 Doi:10.1016/j.maturitas.2017.11.014 DOI: https://doi.org/10.1016/j.maturitas.2017.11.014

Kopeika J, Oyewo A, Punnialingam S, Reddy N, Khalaf Y, Howard J, . . . Oteng-Ntim E. Ovarian reserve in women with sickle cell disease. PLoS One 2019;14(2):e0213024 Doi:10.1371/journal.pone.0213024 DOI: https://doi.org/10.1371/journal.pone.0213024

Karakus S, Sahin A, Durmaz Y, Aydin H, Yildiz C, Akkar O, . . . Cetin A. Evaluation of ovarian reserve using anti-müllerian hormone and antral follicle count in Sjögren's syndrome: Preliminary study. J Obstet Gynaecol Res 2017;43(2):303-307 Doi:10.1111/jog.13216 DOI: https://doi.org/10.1111/jog.13216

Pilone V, Tramontano S, Renzulli M, Monda A, Cutolo C, Romano M and Schiavo L. Evaluation of anti-Müller hormone AMH levels in obese women after sleeve gastrectomy. Gynecol Endocrinol 2019;35(6):548-551 Doi:10.1080/09513590.2018.1559285 DOI: https://doi.org/10.1080/09513590.2018.1559285

Özalp Akın E and Aycan Z. Evaluation of the Ovarian Reserve in Adolescents with Hashimoto’s Thyroiditis Using Serum Anti-Müllerian Hormone Levels. J Clin Res Pediatr Endocrinol 2018;10(4):331-335 Doi:10.4274/jcrpe.0047 DOI: https://doi.org/10.4274/jcrpe.0047

Downloads

Published

2022-06-13

How to Cite

1.
Aykal G, Uzun N, Derbent AU, Yeğin A. Assessment of Ovarian Reserve in Patients with Migraine. Headache Med [Internet]. 2022 Jun. 13 [cited 2024 Nov. 24];13(2):117-23. Available from: https://headachemedicine.com.br/index.php/hm/article/view/605

Issue

Vol. 13 No. 2 (2022)

Section

Original

License

Copyright (c) 2022 Güzin Aykal, Nurgül Uzun, Aysel Uysal Derbent, Ayşenur Yeğin

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.